CliffBio
biologic

Ajovy

fremanezumab-vfrm

Loss of exclusivitySeptember 2030projected — 12-year biologic exclusivity estimate
CompanyTeva Branded Pharmaceutical Products R&D, Inc.

Drug detail

Brand nameAjovy
Active ingredientfremanezumab-vfrm
Strength225MG/1.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalSeptember 2018
Marketing statusRx

More from Teva Branded Pharmaceutical Products R&D, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ajovy patent cliff — loss of exclusivity September 2030 | CliffBio